Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA vaccination in health care workers and elderly subjects and response to a single dose in previously infected adults

View ORCID ProfileAnu Haveri, Anna Solastie, Nina Ekström, Pamela Österlund, Hanna Nohynek, Tuomo Nieminen, Arto A. Palmu, Merit Melin
doi: https://doi.org/10.1101/2021.12.22.21268273
Anu Haveri
1Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anu Haveri
  • For correspondence: anu.haveri@thl.fi
Anna Solastie
1Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nina Ekström
1Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pamela Österlund
1Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanna Nohynek
1Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tuomo Nieminen
2Department of Information Services, Finnish Institute for Health and Welfare, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arto A. Palmu
3Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Tampere, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Merit Melin
1Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The emergence of SARS-CoV-2 Omicron variant (B.1.1.529) with major spike protein mutations has raised concern over potential neutralization escape and breakthrough infections among vaccinated and previously SARS-CoV-2 infected subjects. We measured cross-protective antibodies against variants in health care workers (HCW, n=20) and nursing home residents (n=9) from samples collected 1-2 months following the booster (3rd) dose. We also assessed the antibody responses in prior to Omicron era infected subjects (n=38) with subsequent administration of a single mRNA vaccine dose. Following booster vaccination HCWs had high IgG antibody concentrations to the spike protein and neutralizing antibodies (NAb) were detectable against all variants. IgG concentrations among the elderly remained lower, and some lacked NAbs against the Beta and Omicron variants. NAb titers were significantly reduced against Delta, Beta and Omicron compared to wild-type virus regardless of age. Vaccination induced high IgG concentrations and variable titers of cross-reactive NAbs in previously infected subjects, whereas NAb titers against Omicron were barely detectable 1-month post-infection. High IgG concentrations with cross-protective neutralizing activity were detected after three COVID-19 vaccine doses in HCWs. However, lower NAb titers seen in the frail elderly suggest inadequate protection against Omicron breakthrough infections, yet protection against severe COVID-19 is expected.

Clinical trial registration EudraCT 2021-004788-29

Competing Interest Statement

Finnish Institute for Health and Welfare has received research funding for unrelated studies from GlaxoSmithKline Vaccines (N.E., A.A.P. and M.M. as investigators), Pfizer (A.A.P.) and Sanofi Pasteur (A.A.P.). The other authors report no potential conflicts of interest.

Funding Statement

This study was funded by the Finnish institute for Health and Welfare and the Academy of Finland (Decision number 336431).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol of the COVID-19 vaccine immunological studies in Finland was approved by the National Committee on Medical Research Ethics (TUKIJA/347/2021) and by the Finnish Medicines Agency Fimea as the regulatory authority (European Union clinical trials database code of EudraCT 2021-004788-29). For the follow-up of COVID-19, the study protocol of the serological population study of the coronavirus epidemic was approved by the ethical committee of the Hospital District of Helsinki and Uusimaa (HUS/1137/2020).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data subject to third party restrictions. The data that support the findings of this study are available from Finnish Social and Health Data Permit Authority Findata. Restrictions apply to the availability of these data, which were used under license for this study under informed consent form. Anonymized data are available after permission by Findata.

  • Abbreviations

    BAU
    Binding antibody unit concentration
    COVID-19
    Coronavirus Disease 2019
    GMC
    Geometric mean concentration
    GMT
    Geometric mean titer
    HCW
    Health care worker
    MNT
    Microneutralization test
    mRNA
    Messenger ribonucleic acid
    NAb
    Neutralizing antibody
    RBD
    Receptor-binding domain
    SARS-CoV-2
    Severe acute respiratory syndrome coronavirus 2
    SFL
    Full length spike glycoprotein
    anti-S IgG
    IgG antibodies to spike protein
    VE
    Vaccine effectiveness
    VOC
    Variants of concern
    WT
    Wild-type
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted December 24, 2021.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA vaccination in health care workers and elderly subjects and response to a single dose in previously infected adults
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA vaccination in health care workers and elderly subjects and response to a single dose in previously infected adults
    Anu Haveri, Anna Solastie, Nina Ekström, Pamela Österlund, Hanna Nohynek, Tuomo Nieminen, Arto A. Palmu, Merit Melin
    medRxiv 2021.12.22.21268273; doi: https://doi.org/10.1101/2021.12.22.21268273
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA vaccination in health care workers and elderly subjects and response to a single dose in previously infected adults
    Anu Haveri, Anna Solastie, Nina Ekström, Pamela Österlund, Hanna Nohynek, Tuomo Nieminen, Arto A. Palmu, Merit Melin
    medRxiv 2021.12.22.21268273; doi: https://doi.org/10.1101/2021.12.22.21268273

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (174)
    • Allergy and Immunology (421)
    • Anesthesia (97)
    • Cardiovascular Medicine (901)
    • Dentistry and Oral Medicine (170)
    • Dermatology (102)
    • Emergency Medicine (257)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
    • Epidemiology (8790)
    • Forensic Medicine (4)
    • Gastroenterology (405)
    • Genetic and Genomic Medicine (1864)
    • Geriatric Medicine (179)
    • Health Economics (388)
    • Health Informatics (1292)
    • Health Policy (644)
    • Health Systems and Quality Improvement (492)
    • Hematology (207)
    • HIV/AIDS (395)
    • Infectious Diseases (except HIV/AIDS) (10567)
    • Intensive Care and Critical Care Medicine (564)
    • Medical Education (193)
    • Medical Ethics (52)
    • Nephrology (218)
    • Neurology (1756)
    • Nursing (103)
    • Nutrition (266)
    • Obstetrics and Gynecology (343)
    • Occupational and Environmental Health (461)
    • Oncology (965)
    • Ophthalmology (283)
    • Orthopedics (107)
    • Otolaryngology (177)
    • Pain Medicine (118)
    • Palliative Medicine (43)
    • Pathology (264)
    • Pediatrics (557)
    • Pharmacology and Therapeutics (266)
    • Primary Care Research (219)
    • Psychiatry and Clinical Psychology (1845)
    • Public and Global Health (3986)
    • Radiology and Imaging (655)
    • Rehabilitation Medicine and Physical Therapy (344)
    • Respiratory Medicine (535)
    • Rheumatology (215)
    • Sexual and Reproductive Health (178)
    • Sports Medicine (166)
    • Surgery (197)
    • Toxicology (37)
    • Transplantation (106)
    • Urology (80)